Second-generation antipsychotics for the treatment of disruptive behaviour disorders in children: a systematic review (Q38066274)

28 August 2017

1 reference

title

Second-generation antipsychotics for the treatment of disruptive behaviour disorders in children: a systematic review (English)

1 reference

28 August 2017

Tamara Pringsheim

1 reference

28 August 2017

Daniel Gorman

series ordinal

1 reference

28 August 2017

language of work or name

English

0 references

publication date

1 December 2012

1 reference

Canadian Journal of Psychiatry

28 August 2017

published in

1 reference

28 August 2017

1 reference

28 August 2017

1 reference

28 August 2017

page(s)

722-727

1 reference

The pharmacoepidemiology of antipsychotic medications for Canadian children and adolescents: 2005-2009.

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F070674371205701203

National trends in the outpatient treatment of children and adolescents with antipsychotic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371205701203

Current methods of the US Preventive Services Task Force: a review of the process

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371205701203

Metabolic and neurological complications of second-generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371205701203

Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371205701203

Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371205701203

A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371205701203

A double-blind pilot study of risperidone in the treatment of conduct disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371205701203

Age onset subtypes of obsessive compulsive disorder: differences in clinical response to treatment with clomipramine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371205701203

Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371205701203

Psychopharmacology and aggression. I: A meta-analysis of stimulant effects on overt/covert aggression-related behaviors in ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371205701203

Stimulant-responsive and stimulant-refractory aggressive behavior among children with ADHD

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371205701203

Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371205701203

Ten years of antipsychotic prescribing to children: a Canadian population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371205701203

Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371205701203

Risperidone in children with autism and serious behavioral problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371205701203

Survey of atypical antipsychotic prescribing by Canadian child psychiatrists and developmental pediatricians for patients aged under 18 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371205701203

Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371205701203

Experts' recommendations for treating maladaptive aggression in youth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371205701203

Psychosocial interventions for disruptive and aggressive behaviour in children and adolescents: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371205701203

10.1177/070674371205701203

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference